Earnings per share of the pharma major, with a face value of Rs 2 each, stood at Rs 4.12.

In November 2017, there were 39 deals worth USD 3.2 billion.

Here is a list of top stocks that are likely to be in focus in today's trading session.

For the leverage to be more in the future, we need to have more unlocking in the US pipeline, which is what most analysts are also saying.

As valuation looks comfortable, market experts believe it is a good time to enter the market at current valuation and reap the benefits of ...

India will continue to be the largest market for Cipla and we hope to cross the $1 billion mark in India relatively soon.

Last week Dr. Reddy's acquired a portfolio of eight complex generics in the US from Teva in a deal worth $350 million.

"Cipla FY16 guidance of 20-22 per cent revenue growth and 100 to 150 bps margin improvement for this year does not include InvaGen"

Generics sales in the US, launch of inhalers in the UK and a ramp up from its acquisitions are key positive factors to look forward to.

The S&P BSE Sensex recouped losses after falling as much as 133 points in opening trade on Wednesday following muted trend seen in other As...

Indian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.

Acquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.

We have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.

Cipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...

People close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.

Glenmark Pharmaceuticals is rapidly scaling up its US market product pipeline with its latest agreement with the US-based generic player.

Pharma major Ranbaxy Laboratories Ltd has entered into a strategic partnership with US-based Invagen Pharmaceuticals Inc.